ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 898

Nuclear Receptor Related 1 Induces Synovial Hyperplasia Via Transcriptional Regulation of Novel Target Genes

Kimberlee S. Mix, Biological Sciences, Loyola University New Orleans, New Orleans, LA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Nuclear hormone receptor, synovial cells, synovial fluid and transcription factor

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose: Nuclear receptor related 1 (NURR1 / NR4A2) is an orphan member of the nuclear receptor super-family that functions as a constitutively active transcription factor. This receptor has critical functions in the central nervous system, where it is required for the proper development of dopaminergic neurons. Furthermore, recent studies suggest that NURR1 promotes inflammatory diseases such as cancer, multiple sclerosis, and diabetes. We have documented over-expression of NURR1 in inflamed synovial tissues and cartilage from patients with rheumatoid arthritis and osteoarthritis. NURR1 is rapidly and potently induced by inflammatory cytokines, suggesting that this receptor may promote disease progression and tissue destruction.  We have recently demonstrated that NURR1 induces a hyperplastic phenotype in fibroblast-like synoviocytes by increasing proliferation, anchorage-independent growth, and invasion.   In the current study, we seek to elucidate the molecular mechanisms of NURR1 and identify downstream transcriptional targets of this receptor that may contribute to synovitis and cartilage degradation. 

Methods: To achieve elevated levels of NURR1 similar to those observed in inflamed synovial tissues, NURR1 cDNA was transduced into normal human synoviocytes.  Transcriptional activity was confirmed by the activation of a consensus NURR1 reporter construct. Quantitative RT-PCR arrays were used to identify genes that were differentially regulated by NURR1. 

Results: Paralleling the effects of TNF-alpha, NURR1 regulates a subset of genes involved in angiogenesis, proliferation, and apoptosis. NURR1 potently induces expression of prolactin (300-fold), a peptide hormone that enhances synoviocyte activation and lymphocyte recruitment.   Angiopoietin-1, a ligand for endothelium-specific tyrosine kinase receptors involved in synovial angiogenesis was induced by NURR1 (6-fold). Expression of the tyrosine kinase receptor TEK was also induced (30-fold), suggesting activation of an autocrine signaling pathway in synoviocytes.  Raf kinase and the downstream mitogenic transcription factor c-Myc were both induced 3-fold by NURR1. Furthermore, the tumor suppressor gene p53 was synergistically repressed by NURR1 and TNF-alpha, suggesting that NURR1 may block DNA repair mechanisms and prevent apoptosis of synoviocytes.

Conclusion: Taken together, we have identified a novel set of NURR1 target genes that converge on multiple pathways regulating synovial hyperplasia.  We hypothesize that antagonizing NURR1 activity with a small molecule inhibitor may provide an innovative strategy to block pannus formation and tissue destruction.


Disclosure:

K. S. Mix,
None;

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nuclear-receptor-related-1-induces-synovial-hyperplasia-via-transcriptional-regulation-of-novel-target-genes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology